THROMBOTIC THROMBOCYTOPENIC PURPURA
Clinical trials for THROMBOTIC THROMBOCYTOPENIC PURPURA explained in plain language.
Never miss a new study
Get alerted when new THROMBOTIC THROMBOCYTOPENIC PURPURA trials appear
Sign up with your email to follow new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in preventing deadly blood clot relapses in japanese patients
Disease control CompletedThis study tested a drug called caplacizumab in 21 Japanese adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. The goal was to see if the drug could prevent the disease from coming back. Participants received the drug …
Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA
Phase: PHASE2, PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New hope for TTP patients: drug combo may replace plasma exchange
Disease control CompletedThis study tested whether a combination of caplacizumab and immunosuppressive drugs can treat immune-mediated thrombotic thrombocytopenic purpura (iTTP) without the usual first-line plasma exchange. Fifty-one adults with iTTP received the drug combo for up to 12 weeks, followed b…
Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC